• Intralytix develops bacteriophage-based technologies for food safety, nutraceutical, animal health, and human therapeutic applications
  • The company's product portfolio includes eight products (of which seven are commercialized), targeting common pathogens like ListeriaSalmonella, Shigella spp....

This item has been archived in line with our efforts to keep our content relevant and up to date for our readership. For further assistance, please contact your Customer Success Manager or email Thank you!

Related Research


Company Profile | March 29, 2022

Novolyze develops surrogate microorganisms that mimic the behavior of foodborne pathogens for industrial food safety validation; initially focusing on developing substitutes for Salmonella, Listeria, E. coli, and Cronobacter It claims differentiation in its ability to manufacture surrogate ... Not part of subscription

Better Juice

Company Profile | April 20, 2022

Develops immobilized microorganisms for the bioconversion of monosaccharides and disaccharides in fruit juices into nondigestible forms; continuous process claims to result in a 30% to 80% reduction in sugar So far, raised USD 8 million in funding led by iAngels and The Kitchen FoodTech Hub ... Not part of subscription

Cura Global Health

Company Profile | April 26, 2022

Develops nutritional mineral supplements and ingredients based on fermentation of filamentous fungi like Aspergillus oryzae or Aspergillus niger Claims differentiation in its fermentation‑based approach, which results in whole‑food minerals and slow release of bioavailable iron Has three ... Not part of subscription